This week’s Endocrinology update highlights regulatory progress in type 1 diabetes, advances in cell therapy and metabolic disease innovation, emerging clinical data across rare endocrine disorders, and growing attention to diabetes classification and treatment pathways.
In Today’s Newsletter
Dive deeper
🧬 Syntax Bio and Mayo Clinic advance T1D cell therapy [1] [US • 09 Jun 2026]
https://www.businesswire.com/news/home/20260609294223/en/Syntax-Bio-Announces-Collaboration-with-Mayo-Clinic-to-Advance-Pancreatic-Cell-Therapy-for-Type-1-Diabetes
Context: Syntax Bio and Mayo Clinic formed an R&D collaboration focused on stem cell-derived pancreatic cell therapies for type 1 diabetes.
Key point: Syntax Bio plans to use Cellgorithm to guide iPSCs into beta cells, while Mayo Clinic supports pancreatic biology and preclinical functional testing.
Implication: Signals pipeline investment and modality expansion.
💉 Stevanato launches Deora pen injector for diabetes and weight management [2] [08 Jun 2026]
https://www.businesswire.com/news/home/20260608096966/en/Stevanato-Group-Introduces-Deora-a-Pen-Injector-for-Subcutaneous-Delivery-in-Diabetes-and-Weight-Management
Context: Deora is a fixed-dose, multi-use pen injector for subcutaneous therapies, including diabetes and weight management.
Key point: The device uses a pull-push mechanism, supports fixed-dose volumes up to 0.75 mL, and is compatible with 1.5 mL and 3 mL cartridges.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
🛡️ Sanofi Tzield wins US stage 3 T1D accelerated approval [3] [US • 13 Jun 2026]
https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-12-22-09-58-3311349
Context: FDA granted accelerated approval for Tzield (teplizumab-mzwv) in children aged 8–17 recently diagnosed with stage 3 type 1 diabetes.
Key point: Approval was based on PROTECT Phase 3 and broader clinical data, with reduced C-peptide decline versus placebo.
Implication: May influence prescriber choice and payer reviews pending full data.
🌍 ADA and IDF spotlight malnutrition-related diabetes [4] [07 Jun 2026]
https://www.adameetingnews.org/joint-ada-idf-symposium-to-address-malnutrition-related-diabetes-diagnosis-treatment-and-research-needs/
Context: ADA and IDF planned a joint symposium on malnutrition-related diabetes, also referred to as proposed type 5 diabetes.
Key point: Speakers highlighted diagnosis, phenotyping, treatment gaps, and research needs for people living with the disease worldwide.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
⚖️ Rhythm setmelanotide shows interim PWS Phase 2 benefit [5] [US • 13 Jun 2026]
https://investingnews.com/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-trial-of-setmelanotide-in-patients-with-prader-willi-syndrome-at-endo-2026/
Context: Rhythm reported interim 6-month Phase 2 data for setmelanotide in 18 enrolled patients aged 6–23 with Prader-Willi syndrome.
Key point: Setmelanotide was associated with BMI, body composition, hyperphagia, and anxiousness improvements, with safety consistent with its known profile.
Implication: May influence prescriber choice and payer reviews pending full data.
🧠 Lundbeck asedebart shows Cushing’s disease Phase 2 signal [6] [US • 14 Jun 2026]
https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-new-phase-ii-asedebart-data-in-cushing-s-disease-at-endo-2026,c4362170
Context: Lundbeck presented preliminary Phase 2 Part A data for asedebart, an anti-ACTH monoclonal antibody, in adults with Cushing’s disease.
Key point: UFC normalized in 7 of 8 evaluable patients after individualized IV dose titration; no new safety signals were observed.
Implication: May influence prescriber choice and payer reviews pending full data.
🫀 OrsoBio TLC-2716 reduces triglycerides in SHTG and MASLD [7] [US • 14 Jun 2026]
https://www.businesswire.com/news/home/20260614487129/en/OrsoBio-Presents-Positive-Phase-2a-Data-for-LXR-Inverse-Agonist-TLC-2716-in-Severe-Hypertriglyceridemia-and-MASLD-at-ENDO-2026
Context: OrsoBio reported Phase 2a data for TLC-2716, an oral liver-targeted LXR inverse agonist, in severe hypertriglyceridemia and MASLD.
Key point: TLC-2716 met the primary endpoint, with placebo-adjusted triglyceride reductions after 4 weeks and improvements in remnant cholesterol and liver fat.
Implication: May influence prescriber choice and payer reviews pending full data.
📈 Crinetics PALSONIFY shows durable acromegaly control [8] [US • 14 Jun 2026]
https://www.globenewswire.com/news-release/2026/06/14/3311468/0/en/Crinetics-Presents-Long-Term-Data-at-ENDO-2026-Confirming-PALSONIFY-paltusotine-Provides-Durable-Consistent-Acromegaly-Control.html
Context: Crinetics presented long-term PATHFNDR-1 and PATHFNDR-2 open-label extension data for PALSONIFY (paltusotine) in acromegaly.
Key point: Up to 2 years of treatment maintained or lowered IGF-1 levels, with stable symptoms and stable or reduced pituitary tumor volume.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- Type 1 diabetes is seeing movement across immunotherapy and regenerative medicine, with Tzield’s new US use and Syntax Bio’s beta-cell collaboration.
- ADA and IDF are pushing malnutrition-related diabetes toward clearer classification, diagnosis, and research pathways.
- ENDO 2026 highlighted rare endocrine pipeline momentum across Prader-Willi syndrome, Cushing’s disease, and acromegaly.
- Metabolic disease innovation remains broad, spanning delivery devices, lipid-lowering mechanisms, MASLD, and obesity-adjacent conditions.
- Several updates remain interim, early-phase, or open-label, so interpretation depends on full datasets and confirmatory studies.
📚 View the full Endocrinology archive on our research hub page
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Endocrinology news from the past two weeks, curated by the LucidQuest team.
FAQ
What changed for Sanofi Tzield in type 1 diabetes?
FDA granted accelerated approval for Tzield in children aged 8–17 recently diagnosed with stage 3 type 1 diabetes. Continued approval may depend on confirmatory evidence of clinical benefit. [3]
What is Syntax Bio doing with Mayo Clinic?
Syntax Bio and Mayo Clinic are collaborating on stem cell-derived pancreatic beta cell therapy for type 1 diabetes. Syntax Bio will use Cellgorithm, while Mayo Clinic supports preclinical diabetes model testing. [1]
What is malnutrition-related diabetes?
ADA and IDF described malnutrition-related diabetes as a proposed diabetes type, also referred to as type 5 diabetes. The symposium focused on diagnosis, treatment, and research needs. [4]
What did Rhythm report for setmelanotide in Prader-Willi syndrome?
Rhythm reported positive interim 6-month Phase 2 data in patients with PWS, including improvements across BMI, hyperphagia, body composition, and behavior-related measures. The 52-week trial remains ongoing. [5]
What is asedebart, and what did Lundbeck report?
Asedebart is an investigational anti-ACTH monoclonal antibody for Cushing’s disease. Lundbeck reported UFC normalization in 7 of 8 evaluable patients after IV dose titration in Phase 2 Part A. [6]
What did Crinetics show for PALSONIFY?
Crinetics reported long-term open-label extension data showing PALSONIFY maintained or lowered IGF-1 levels and supported stable symptoms in acromegaly. [8]
Entities / Keywords
Syntax Bio, Mayo Clinic, Cellgorithm, pancreatic beta cell therapy, induced pluripotent stem cells, iPSCs, type 1 diabetes, T1D
Stevanato Group, Deora, pen injector, subcutaneous delivery, diabetes, weight management, GLP-1, incretin-based therapies
Sanofi, Tzield, teplizumab-mzwv, Teizeild, PROTECT, BETA-PRESERVE, stage 3 type 1 diabetes, C-peptide
ADA, American Diabetes Association, IDF, International Diabetes Federation, malnutrition-related diabetes, proposed type 5 diabetes
Rhythm Pharmaceuticals, setmelanotide, IMCIVREE, MC4R agonist, Prader-Willi syndrome, PWS, hyperphagia, BMI
Lundbeck, asedebart, Lu AG13909, anti-ACTH monoclonal antibody, Cushing’s disease, urinary free cortisol, UFC
OrsoBio, TLC-2716, LXR inverse agonist, severe hypertriglyceridemia, SHTG, MASLD, remnant cholesterol, liver fat
Crinetics, PALSONIFY, paltusotine, PATHFNDR-1, PATHFNDR-2, ACROBAT, acromegaly, IGF-1, somatostatin receptor agonist
References
- https://www.businesswire.com/news/home/20260609294223/en/Syntax-Bio-Announces-Collaboration-with-Mayo-Clinic-to-Advance-Pancreatic-Cell-Therapy-for-Type-1-Diabetes
- https://www.businesswire.com/news/home/20260608096966/en/Stevanato-Group-Introduces-Deora-a-Pen-Injector-for-Subcutaneous-Delivery-in-Diabetes-and-Weight-Management
- https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-12-22-09-58-3311349
- https://www.adameetingnews.org/joint-ada-idf-symposium-to-address-malnutrition-related-diabetes-diagnosis-treatment-and-research-needs/
- https://investingnews.com/rhythm-pharmaceuticals-presents-positive-interim-six-month-data-from-phase-2-trial-of-setmelanotide-in-patients-with-prader-willi-syndrome-at-endo-2026/
- https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-new-phase-ii-asedebart-data-in-cushing-s-disease-at-endo-2026,c4362170
- https://www.businesswire.com/news/home/20260614487129/en/OrsoBio-Presents-Positive-Phase-2a-Data-for-LXR-Inverse-Agonist-TLC-2716-in-Severe-Hypertriglyceridemia-and-MASLD-at-ENDO-2026
- https://www.globenewswire.com/news-release/2026/06/14/3311468/0/en/Crinetics-Presents-Long-Term-Data-at-ENDO-2026-Confirming-PALSONIFY-paltusotine-Provides-Durable-Consistent-Acromegaly-Control.html